The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.

Weinblatt, ME, Mease, P, Mysler, E et al. (7 more authors) (2015) The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis and Rheumatology, 67 (10). pp. 2591-2600. ISSN 2326-5191

Abstract

Metadata

Authors/Creators:
  • Weinblatt, ME
  • Mease, P
  • Mysler, E
  • Takeuchi, T
  • Drescher, E
  • Berman, A
  • Xing, J
  • Zilberstein, M
  • Banerjee, S
  • Emery, P
Dates:
  • Published: 1 October 2015
  • Accepted: 11 June 2015
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Clinical Musculoskeletal Medicine (LIRMM) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 18 Feb 2016 11:14
Last Modified: 04 Nov 2016 00:27
Published Version: http://dx.doi.org/10.1002/art.39249
Status: Published
Publisher: Wiley
Identification Number: https://doi.org/10.1002/art.39249
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics